Search is Powered by Google
Lymphoma / Leukemia News

Researchers Find New Clues To Risk Of Hodgkin Lymphoma

Main Category: Lymphoma / Leukemia
Article Date: 03 Apr 2008 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:3 and a half stars

3.5 (2 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

A long-term study of twins has led University of Southern California (USC) researchers to find potential links between Hodgkin lymphoma and levels of an immune response protein (interleukin-12).

"We found that lower levels of the protein interleukin-12, involved in fighting intracellular infections, increases susceptibility to young adult Hodgkin lymphoma," says Wendy Cozen, D.O., M.P.H, associate professor of preventive medicine at the Keck School of Medicine of USC. "

Cozen is lead author on the study entitled, "Interleukin-2, interleukin-12, and interferon-γ levels and risk of young adult Hodgkin lymphoma," published in the April 1 issue of the journal, Blood.

The study is accompanied by an editorial entitled "Hodgkin twins: double good, double trouble," by Richard F. Ambinder of the Johns Hopkins School of Medicine.

The work is based on patient populations found in the International Twin Study and California Twin Program, unique registries of twin pairs developed and maintained in the Department of Preventive Medicine at USC.

Hodgkin lymphoma is the most common type of cancer among young women and the second most common type among young men. But while the 5-year survival rate is high compared to that of other cancers, the treatment may cause complications later in life.

According to Cozen, this study, along with a previous one her group published in 2007, provides the first clear evidence that individual differences in immune response (via cytokine secretion) may lead to the development of Hodgkin lymphoma.

"We previously showed that there is a substantial genetic risk for adolescent and young adult Hodgkin lymphoma, and that another immune response protein (interleukin-6) was related to risk," says Cozen. "We are pursuing the hypothesis that variations in genes control the secretion of these immune response proteins (cytokines) predicting Hodgkin lymphoma risk."

Eventually, based on the group's current work, researchers may be able to develop novel treatments to correct the abnormal immune response thereby offering alternatives to current therapy.

Cozen and her group are conducting an expanded study among adolescent and young adult Hodgkin lymphoma patients and their parents in Los Angeles.

The group is studying these genes and others that control the immune response in hopes of confirming their previous results and to further define the inherited patterns that explain the genetic part of the risk.

Cozen adds that colleagues from the National Cancer Institute and Washington University in St. Louis, will also be studying early exposures to infectious agents such as bacteria and viruses, which may interact with the immune system leading to Hodgkin lymphoma.

Funding for this research came from The National Cancer Institute.

Wendy Cozen, Parkash S. Gill, Muhammad T. Salam, Alexandra Nieters, Rizwan Masood, Myles G. Cockburn, W. James Gauderman, Otoniel Martínez-Maza, Bharat N. Nathwani, Malcolm C. Pike, David J. Van Den Berg, Ann S. Hamilton, Dennis M. Deapen, and Thomas M. Mack. "Interleukin-2, interleukin-12, and interferon-γ levels and risk of young adult Hodgkin lymphoma," Blood 2008 DOI: 10.1182/blood-2007-08-106872

University of Southern California Health Sciences
1975 Zonal Ave., #400
Los Angeles, CA 90033
United States
http://www.scuhs.edu




Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Schizophrenia

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Monitoring CML image Monitoring CML

A wide range of laboratory tests is used to monitor a patient's response to therapy for chronic myeloid leukemia. Listen to experts explain the tests and their range of sensitivity...

View more videos...